 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
7 News |  |
- | F14512 / Pierre Fabre
Journal: Prognostic value of pretreatment plasma D-dimer level in dogs with intermediate to high-grade non-Hodgkin lymphoma. (Pubmed Central) - Sep 24, 2021
This study suggests that pretreatment plasma D-dimer level can serve as a predictor of prognosis in dogs with intermediate to high-grade NHL. Further studies are warranted to confirm these findings.
- || etoposide IV / Generic mfg., F14512 / Pierre Fabre
Clinical, Journal: Randomized, double-blind trial of F14512, a polyamine-vectorized anticancer drug, compared with etoposide phosphate, in dogs with naturally occurring lymphoma. (Pubmed Central) - Mar 7, 2020
F14512 showed strong therapeutic efficacy against spontaneous NHL and exhibited a clinical benefice in Pgp-overexpressing lymphoma superior to etoposide phosphate. The results clearly justify the evaluation of F14512 in human clinical trials.
- || F14512 / Pierre Fabre
Clinical, P1 data, Journal: Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer. (Pubmed Central) - Feb 9, 2020
Conclusion Although there was some encouraging efficacy signal, grade 4 neutropenia led to complications and it was decided to stop the study. A DL below 5 mg/m/day was not tested as this would not allow reaching the minimum serum concentration needed for the pharmacological activity of the drug.